ABSTRACT
INTRODUCTION
ALS is a fatal, typically late-onset neurodegenerative disorder associated with the dysfunction or death of motor neurons. Unfortunately, there is no primary therapy for this disease and its pathogenesis is poorly understood. The disease is most often sporadic, but about 10% of the patients inherit the disease (1) Valosin-containing protein (VCP) and C9orf72 have been identified in familial forms of ALS (2) (3) (4) (5) (6) (7) (8) . The existence of inherited ALS cases has provided excellent inroads towards unraveling the molecular pathology of the motor neuron diseases. Significantly, transgenic mice expressing mutant SOD1 have recapitulated the motor defects observed in ALS patients (9) . Use of these mice has been crucial in characterizing familial and sporadic ALS disease mechanisms (10) .
However, therapeutic efficacy in these animals has been poorly predictive of human efficacy.
Therefore, it is crucial to create model systems associated with other mutations in ALS and
analyze the resulting phenotypes.
ALS8 is a slowly progressive and late-onset dominant form of ALS first identified in a large Brazilian family (11) . The family shows clinical heterogeneity with different clinical courses, such as late-onset spinal muscular atrophy (SMA), slowly progressive ALS, and typical severe ALS with rapid progression (11, 12) . They are all found to have the same mutation (P56S) in the VAPB gene (11) . In addition, recently, other rare mutations in the VAPB gene were also found to cause ALS (13, 14) .
Human VAPB is evolutionarily conserved, with homologs in numerous species (15) , including yeast scs2 and Drosophila vap. The Vap protein contains an amino (N)-terminal domain, called the major sperm protein (MSP) domain (16, 17) and a transmembrane domain that anchors the protein in the ER (18) . The N-terminal MSP domain of Vap is virtually identical in structure to the abundant MSP protein in C. elegans (19) , where MSP functions as a secreted ligand (20, 21) . Indeed, the MSP domain of Vap is cleaved and secreted from neurons (22, 23) .
The cleaved MSP acts as a ligand for growth cone guidance receptors expressed on muscle surfaces in C. elegans (23) . Significantly, Vap proteins also have autonomous functions as they are ER associated proteins. They have been shown to function in neurite extension (24) , the development of the neuromuscular junctions (25) , ER-to Golgi protein trafficking (26) (27) , and calcium homeostasis in the mitochondria (28). However, it is still not clear how these functions are relevant to the pathology in motor neuron disease.
Transgenic mice overexpressing P56S mutant human VAPB protein with neuron-specific and ubiquitous promoters have been generated (29-32). Although these mice have provided insights into the toxic property of the mutant proteins, only transgenic mice expressing P56S VAPB driven by Thy1.2 promoter showed motor behavior defects (30). Thus, the pathogenesis associated with the mutant VAPB protein remains unclear. Moreover, it has not been possible to undertake human pathological studies in ALS8/motor neuron disease associated with the mutant VAPB as the disease shows a late onset ALS or SMA (average 50 years old) with a slowly progressive course (11, 12) .
Expressing the mutant proteins in the correct temporal and spatial expression patterns will help us dissect the mechanisms of cell-specific vulnerability and the effects of the pathological mutations. Here we report generation and characterization of Vapb knock-in mice replacing wild type Vapb with the mutant (P56S) Vapb to faithfully create features of the human ALS8/SMA associated with P56S VAPB. Significantly, the Vapb knock-in mice exhibit late-onset motor behavior defects as observed in the patients associated with the P56S VAPB. The Vapb knock-in mice also display many cellular pathological features implicated in ALS, including accumulation of ubiquitinated proteins, ER stress, and autophagic response before onset of obvious motor behavior defects. We propose that ER stress and autophagic response are key early pathogenic processes in the disease.
RESULTS

Generation of Vapb P56S knock-in mice
To elucidate the pathological mechanism underlying motor neuron diseases associated with P56S Fig. S2 ). Hence, we have established that P56S knock-in mice exhibit slowly progressive defects in motor behavior analogous to those observed in human motor neuron disease associated with P56S VAPB.
The P56S mutant Vapb knock-in mice show mild and chronic neurogenic defects in muscle pathology Analysis of muscle biopsies from ALS8 patients show defects consistent with a neurogenic pattern including groups of small angulated fibers (11, 12) . To examine if the ALS8 knock-in mice show neurogenic defects, we performed histological analysis of the soleus muscles of Vapb WT and Vapb P56S mice that were used in the behavior tests shown in Figure 2 . We find that 8 of internal nuclei in muscle fibers of Vapb P56S (arrow heads in Figure 2D and 2F, quantification in Figure 2G ). We, however, did not observe significant differences in the staining of muscle and Vapb P56S mice show a fragmented appearance of postsynaptic areas (Fig. 3B, 3C ). As shown in Figure 3D1 , we found a significant increase in the total number of (Fig. 3D2 ) and the number of faintly clustered or ectopic AChR staining clusters ( Fig. 3D3 and Fig. 3D4 ) (42) . We observed a tendency towards an increased number of uncovered postsynapses (AChR) (Fig. 3D2 ) and ectopic AChR (Fig. 3D4) 
VAPB protein is predominantly expressed in lower motor neurons
Human ALS8 patients affected with the P56S mutant VAPB gene show weakness and muscle atrophy associated with defects in lower motor neurons rather than upper motor neurons (12) .
To determine whether the distribution of VAPB protein might contribute to the selective vulnerability of motor neurons in ALS8, we examined expression of VAPB in the CNS and spinal cord in mice. To assess the specificity of VAPB antibody (33), we performed immunostaining of wild type and mutant mice carrying a gene trap mutation in the Vapb locus (Vapb GT ). The Vapb GT mice were generated from ES cells carrying a gene-trapping vector inserted into the Vapb locus ( Fig. S3A ) (45, 46) . We confirmed that Vapb GT mice are almost
Vapb null with immunofluorescence and western blotting using VAPB antibody (Fig. 4A , B and shows little or no expression in glia cells (Fig. 4C ). VAPB is also highly expressed in the motor neurons of the caudal brainstem ( Fig. 4E ), which is co-labelled with Choline Acetyltransferase antibody (data not shown). In contrast, VAPB is barely expressed in the cerebellum (Fig. 4F ), the cerebrum (including cortical motor neurons labelled with CITP2) (Fig. 4G ), and the hippocampus ( Fig. 4H ). In summary, the data indicate that VAPB is highly expressed in the lower motor neurons, which are the most vulnerable to dysfunction or degeneration in ALS8 or SMA.
The P56S mutation causes VAPB protein to be mislocalized into cytoplasmic inclusions
We, and others, have shown that the P56S mutation causes VAPB protein to be mislocalized into cytoplasmic inclusions when the mutant protein is overexpressed in flies and mice (22, 29, 30 VAPB levels decrease concomitantly with the disease's progression in the SOD1 mouse model (47) , and sporadic ALS patients have been reported to have decreased levels of the VAPB protein (47, 61) . Defects in ER protein homeostasis and ER stress are also commonly observed in ALS patients (62) (63) (64) , suggesting that loss of VAPB function in the ER might cause common pathology in ALS.
Interestingly, ALS8 mutation might also cause gain of function in certain situations in the ALS8 knock-in mice. We observed that the ALS8 knock-in mice show an increased number of synaptic boutons/varicosities. In flies, hypomorphic and null mutations in Vap cause a severe decrease in numbers of varicosities and an increase in their size at the NMJs (25, 43) .
Conversely, overexpression of drosophila Vap and human VAPB in Drosophila neurons induces a highly significant increase in the number of varicosities (43) , similarity to what we observed in the ALS8 knock-in mice. The data suggests that ALS8 mutation might cause a gain of function in the NMJs, although there is a difference in neurotransmitter, receptors and molecular signals in Drosophila and mice NMJs (65) . Notably, synaptic transmission is maintained in the vap null mutant flies and flies overexpressing human VAPB despite this structural alteration (43) .
Therefore, detailed studies are necessary to conclude how defects in morphology contribute to the pathology in ALS8.
A key observation in this study is that VAPB accumulates in the autophagosome in the motor neurons of the ALS8 knock-in mice, accompanying increased levels of P62/SQSTM1 and Alternatively, upregulation of autophagic responses might induce detrimental defects in ALS8 as observed in other neurodegenerative diseases (71) . Autophagic responses might also be a result of ER stress (71, 72) , leading to the core pathology of ALS8.
This knock-in mouse replicates numerous aspects of the human disease, from progressive motor defects to selective motor neuron cellular pathology. Not only will this model allow us to study the mechanism of these varied deficits in vivo, but it provides a more authentic means of testing interventional therapies. These mice could be used, for example, to test the efficacy of compounds that have proven effective in other model organisms on facets of the phenotypes of motor neuron diseases or ALS. (E-H) Staining of dorsal pons (E), cerebellum (F), motor cortex (G) and CA1 of hippocampus (H) with VAPB antibody (E-H), NeuN antibody (E', F' and H') and CITP2 (G'). VAPB is expressed in NeuN positive neurons in the dorsal pons (E-E"), but barely expressed in the cerebellum (F-F") and neurons in the motor cortex (G-G") and hippocampus (H-H"). show higher magnification of (A) and (B), respectively.VAPB WT is colocalized with KDEL, the 
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